SNIPER: A novel assay for human papillomavirus testing among women in Guizhou, China

International Journal of Gynecological Cancer

Volumn 20, Issue 6, 2010, Pages 1006-1010

  Belinson, Suzanne E ^a   Wulan, Na ^b   Li, Ruizhen ^b   Zhang, Wei ^b   Rong, Xuan ^b   Zhu, Yasha ^b   Wu, Ruifang ^b   Belinson, Jerome L ^a  

^a Preventive Oncology International Inc   (United States)

^b PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

Assay; Cervical cancer; Human papillomavirus; Screening

Indexed keywords

SODIUM CHLORIDE; VIRUS DNA; DNA PROBE;

ADULT; ARTICLE; CANCER SCREENING; CHINA; COLPOSCOPY; CROSS-SECTIONAL STUDY; CYTOLOGY; DNA DETERMINATION; FEMALE; FOLLOW UP; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONFIDENCE INTERVAL; DNA PROBE; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; INCIDENCE; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; CYTOLOGICAL TECHNIQUES; DNA PROBES, HPV; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; PAPANICOLAOU TEST;

EID: 77956826425     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181e73092     Document Type: Article

References (17)

1. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20-25.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24:S3/11-25.
4. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353:2101-2104.
5. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439-444.
6. Bollmann R, Bankfalvi A, Griefingholt H, et al. Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: results from 31031 women from the Bonn-region in West Germany. Oncol Rep. 2005;13:915-922.
7. Carozzi FM, Confortini M, Cecchini S, et al. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer. 2005;105:2-7.
8. Dalla Palma P, Pojer A, Girlando S. HPV triage of women with atypical squamous cells of undetermined significance: a 3-year experience in an Italian organized programme. Cytopathology. 2005;16:22-26.
9. Agorastos T, Dinas K, Lloveras B, et al. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecol Oncol. 2005;96:714-720.
10. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol. 2005;32:S34-42.
11. Sankaranarayanan R, Chatterji R, Shastri SS, et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer. 2004;112:341-347.
12. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588.
13. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597.
14. Hoyer H, Scheungraber C, Kuehne-Heid R, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPVand cytology testing in a primary screening setting. Int J Cancer. 2005;116:136-143.
15. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province Cervical Cancer Screening Study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer. 2003;13:819-826.
16. Minghui Huang HH, Fu H, Yang M. Clinical Performance of SNIPPER™ Real-time Fluorescence PCR Assay for the Detection of High-risk HPV Genotypes in Clinical Samples. Presented at the 24th International Papillomavirus Conference & Clinical Workshop; Nov. 3-9, 2007; Beijing, China; Nov. 3-9, 2007.
17. Qing LI LW, Shangying HU, Ruifang WU, et al. Effect of HPV multiplex PCR fluorescence test on cervical cancer screening. China Cancer. 2009;18:315-318.